Patrizio Bortolus

Sedicidodici SRL engages in the research and development of pharmaceuticals. It offers Smart Clot, a new tool for measuring the hemorrhagic and chromogenic of patients affected by cardiovascular diseases and thrombotic-hemorrhagic disorders, and for monitoring the effects of anticoagulation and antiplatelet drug therapy. The company was founded by Patrizio Bortolus, Raul Pietrini, Carlo de Franceschi and Andrea Malacart in 2005 and is headquartered in Pordenone, Italy.

Sedicidodici SRL engages in the research and development of pharmaceuticals. It offers Smart Clot, a new tool for measuring the hemorrhagic and chromogenic of patients affected by cardiovascular diseases and thrombotic-hemorrhagic disorders, and for monitoring the effects of anticoagulation and antiplatelet drug therapy. The company was founded by Patrizio Bortolus, Raul Pietrini, Carlo de Franceschi and Andrea Malacart in 2005 and is headquartered in Pordenone, Italy.

Sedicidodici SRL engages in the research and development of pharmaceuticals. It offers Smart Clot, a new tool for measuring the hemorrhagic and chromogenic of patients affected by cardiovascular diseases and thrombotic-hemorrhagic disorders, and for monitoring the effects of anticoagulation and antiplatelet drug therapy. The company was founded by Patrizio Bortolus, Raul Pietrini, Carlo de Franceschi and Andrea Malacart in 2005 and is headquartered in Pordenone, Italy.